Related Experiment Video
Updated: Aug 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Serious Infusion Reactions in Two Adolescents Receiving Bebtelovimab
Megan E Peters1, Jill Strayer2, Ellen R Wald1
1From the Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Monoclonal antibodies like bebtelovimab may cause serious infusion reactions in adolescents with COVID-19. Review available antiviral options for pediatric coronavirus disease 2019 management.
Area of Science:
- Pediatric Infectious Diseases
- Immunology
- Pharmacology
Background:
- Limited data exists on the safety and efficacy of monoclonal antibodies for treating coronavirus disease 2019 (COVID-19) in pediatric populations.
- Prescribers require guidance on appropriate use of these novel therapeutics in children and adolescents.
Purpose of the Study:
- To report cases of infusion reactions to monoclonal antibodies in pediatric patients.
- To review current antiviral treatment options for mild to moderate COVID-19 in pediatric patients.
Main Methods:
- Case report of two adolescent patients experiencing infusion reactions.
- Literature review of available antiviral medications for pediatric COVID-19.
Main Results:
- Two adolescent patients experienced serious infusion reactions during bebtelovimab administration.
- A review of antiviral medications suitable for pediatric use in mild or moderate COVID-19 was conducted.
Conclusions:
- Healthcare providers should be aware of potential serious infusion reactions associated with monoclonal antibody use in pediatric COVID-19 patients.
- A comprehensive understanding of available antiviral therapies is crucial for managing pediatric coronavirus disease 2019.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Allergic Drug Reactions
Allergic Reactions
Factors Affecting Drug Response: Overview
Myocarditis III: Medical Management
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...